PDCD1LG2 and metastatic melanoma: This study recruited patients with unresectable or metastatic melanoma who have not previously received therapy for unresectable or metastatic disease, as well as those who have not received therapy with anti-CTLA4 and/or anti–PD-1/PD-L1/PD-L2 or targeted therapies.